Trial/investigator | Intervention | ClinicalTrials.gov | Status |
---|---|---|---|
Optiprim ANRS 147 (A. Chèret) | 3 vs 5 ARV at AHI | NCT01033760 | Ongoing |
IntensVIH (A. Lafeuillade) | RAL + MRV intensification | NCT00935480 | Ongoing |
Eramune 01 (C. Katlama) | IL7 + intensification RAL/MVC | NCT01019551 | Ongoing |
Eramune 02 (R. Murphy) | Vacc + intensification RAL/MVC | NCT09976404 | Ongoing |
S. Deeks | Disulfiram | NCT01286259 | Ongoing |
D. Margolis | Vorinostat (SAHA) | NCT01319383 | [229], Ongoing |
S. Lewin | Vorinostat (SAHA) | NCT01365065 | Ongoing |
L. Østergaard | Panobinostat | NCT01680094 | Ongoing |
J. Lalezari | ZFN (CCR5) | NCT01252641 | Ongoing |
P. Tebas | ZFN (CCR5) | NCT00842634 | Ongoing |
A. Krishnan | Autologous SC with anti-HIV genes | NCT00569985 | Ongoing |
F. Maldarelli | INFα 2b | NCT01295515 | Ongoing |
Gilead | Romidepsin | NA | To be started |
S. Moreno | Bryostatin | NA | To be started |
H. Hatano | Anti-PDI antibody | NA | To be started |
A. Woolfrey | Intervention autologous HIV resistant cells | NA | To be started |